{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:12:58Z","timestamp":1781687578109,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Video-enabled directly observed therapy (video-DOT) has been proposed as an additional option for treatment provision besides in-person DOT for patients with drug-resistant TB (DRTB) disease. However, evidence and implementation experience mainly originate from well-resourced contexts. This study describes the operationalization of video-DOT in a low-resourced setting in Eswatini facing a high burden of HIV and TB amid the emergence of the COVID-19 pandemic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a retrospectively established cohort of patients receiving DRTB treatment during the implementation of video-DOT in Shiselweni from May 2020 to March 2022. We described intervention uptake (vs. in-person DOT) and assessed unfavorable DRTB treatment outcome (death, loss to care) using Kaplan-Meier statistics and multivariable Cox-regression models. Video-related statistics were described with frequencies and medians. We calculated the fraction of expected doses observed (FEDO) under video-DOT and assessed associations with missed video uploads using multivariable Poisson regression analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 71 DRTB patients eligible for video-DOT, the median age was 39 (IQR 30\u201354) years, 31.0% (<jats:italic>n<\/jats:italic>\u2009=\u200922) were women, 67.1% (<jats:italic>n<\/jats:italic>\u2009=\u200947\/70) were HIV-positive, and 42.3% (<jats:italic>n<\/jats:italic>\u2009=\u200930) were already receiving DRTB treatment when video-DOT became available. About half of the patients (<jats:italic>n<\/jats:italic>\u2009=\u200937; 52.1%) chose video-DOT, mostly during the time when COVID-19 appeared in Eswatini. Video-DOT initiations were lower in new DRTB patients (aHR 0.24, 95% CI 0.12\u20130.48) and those aged\u2009\u2265\u200960 years (aHR 0.27, 95% CI 0.08\u20130.89). Overall, 20,634 videos were uploaded with a median number of 553 (IQR 309\u2013748) videos per patient and a median FEDO of 92% (IQR 84\u201397%). Patients aged\u2009\u2265\u200960 years were less likely to miss video uploads (aIRR 0.07, 95% CI 0.01\u20130.51). The cumulative Kaplan-Meier estimate of an unfavorable treatment outcome among all patients was 0.08 (95% CI 0.03\u20130.19), with no differences detected by DOT approach and other baseline factors in multivariable analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Implementing video-DOT for monitoring of DRTB care provision amid the intersection of the HIV and COVID-19 pandemics seemed feasible. Digital health technologies provide additional options for patients to choose their preferred way to support treatment taking, thus possibly increasing patient-centered health care while sustaining favorable treatment outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-024-11151-4","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T11:01:57Z","timestamp":1717412517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The introduction of video-enabled directly observed therapy (video-DOT) for patients with drug-resistant TB disease in Eswatini amid the COVID-19 pandemic \u2013 a retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Bernhard","family":"Kerschberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Daka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhekiwe","family":"Shongwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themba","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siphiwe","family":"Ngwenya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Danbakli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bheki","family":"Mamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongekile","family":"Nxumalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Sibanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindiwe Mdluli","family":"Dlamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Mabhena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mukooza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Crumley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iza","family":"Ciglenecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debrah","family":"Vambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"11151_CR1","unstructured":"Global tuberculosis report 2023. Geneva, Switzerland: World Health Organization; 2023."},{"key":"11151_CR2","unstructured":"Global tuberculosis report 2021. Geneva, Switzerland: World Health Organization; 2022."},{"key":"11151_CR3","doi-asserted-by":"crossref","unstructured":"Farley JE, Ram M, Pan W, Waldman S, Cassell GH, Chaisson RE et al. Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence. PLoS ONE. 2011 Jul 22 [cited 2013 Jul 25];6(7). http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3142109\/","DOI":"10.1371\/journal.pone.0020436"},{"issue":"s1","key":"11151_CR4","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1086\/518665","volume":"196","author":"CD Wells","year":"2007","unstructured":"Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, et al. HIV infection and multidrug-resistant tuberculosis\u2014the Perfect Storm. J Infect Dis. 2007;196(s1):S86\u2013107.","journal-title":"J Infect Dis"},{"issue":"8","key":"11151_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMra1200894","volume":"368","author":"A Zumla","year":"2013","unstructured":"Zumla A, Raviglione M, Hafner R. Fordham Von Reyn C. Tuberculosis. N Engl J Med. 2013;368(8):745\u201355.","journal-title":"N Engl J Med"},{"key":"11151_CR6","unstructured":"Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development \/ The World Bank; 2017. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK525174\/"},{"key":"11151_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2471\/BLT.06.038927","volume":"85","author":"TR Frieden","year":"2007","unstructured":"Frieden TR, Sbarbaro JA. Promoting adherence to treatment for tuberculosis: the importance of direct observation. Bull World Health Organ. 2007;85:407\u20139.","journal-title":"Bull World Health Organ"},{"issue":"2","key":"11151_CR8","first-page":"103","volume":"7","author":"JCM Macq","year":"2003","unstructured":"Macq JCM, Theobald S, Dick J, Dembele M. An exploration of the concept of directly observed treatment (DOT) for tuberculosis patients: from a uniform to a customised approach. Int J Tuberc Lung Dis. 2003;7(2):103\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"key":"11151_CR9","volume-title":"Module 4: treatment - drug-resistant tuberculosis treatment","author":"WHO consolidated guidelines on tuberculosis","year":"2020","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva, Switzerland: World Health Organization; 2020."},{"issue":"7","key":"11151_CR10","doi-asserted-by":"publisher","first-page":"e1002595","DOI":"10.1371\/journal.pmed.1002595","volume":"15","author":"N Alipanah","year":"2018","unstructured":"Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, et al. Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018;15(7):e1002595.","journal-title":"PLoS Med"},{"key":"11151_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40249-016-0187-9","volume":"5","author":"B Getahun","year":"2016","unstructured":"Getahun B, Wubie M, Dejenu G, Manyazewal T. Tuberculosis care strategies and their economic consequences for patients: the missing link to end tuberculosis. Infect Dis Poverty. 2016;5:93.","journal-title":"Infect Dis Poverty"},{"key":"11151_CR12","doi-asserted-by":"crossref","unstructured":"Am K, Bj APBJNR, C N. M, Economic burden of tuberculosis in Tanzania: a national survey of costs faced by tuberculosis-affected households. BMC Public Health. 2022 Mar 29 [cited 2022 Apr 25];22(1). https:\/\/pubmed.ncbi.nlm.nih.gov\/35351063\/","DOI":"10.1186\/s12889-022-12987-3"},{"key":"11151_CR13","first-page":"100098","volume":"17","author":"RS Garfein","year":"2019","unstructured":"Garfein RS, Doshi RP. Synchronous and asynchronous video observed therapy (VOT) for tuberculosis treatment adherence monitoring and support. J Clin Tuberc Mycobact Dis. 2019;17:100098.","journal-title":"J Clin Tuberc Mycobact Dis"},{"issue":"10","key":"11151_CR14","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.3201\/eid2410.180459","volume":"24","author":"RS Garfein","year":"2018","unstructured":"Garfein RS, Liu L, Cuevas-Mota J, Collins K, Mu\u00f1oz F, Catanzaro DG, et al. Tuberculosis treatment monitoring by video directly observed therapy in 5 health districts, California, USA. Emerg Infect Dis. 2018;24(10):1806\u201315.","journal-title":"Emerg Infect Dis"},{"issue":"10177","key":"11151_CR15","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0140-6736(18)32993-3","volume":"393","author":"A Story","year":"2019","unstructured":"Story A, Aldridge RW, Smith CM, Garber E, Hall J, Ferenando G, et al. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet. 2019;393(10177):1216\u201324.","journal-title":"Lancet"},{"issue":"11","key":"11151_CR16","doi-asserted-by":"publisher","first-page":"e50155","DOI":"10.1371\/journal.pone.0050155","volume":"7","author":"VA Wade","year":"2012","unstructured":"Wade VA, Karnon J, Eliott JA, Hiller JE. Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation. PLoS ONE. 2012;7(11):e50155.","journal-title":"PLoS ONE"},{"issue":"3","key":"11151_CR17","doi-asserted-by":"publisher","first-page":"1602049","DOI":"10.1183\/13993003.02049-2016","volume":"49","author":"H Sinkou","year":"2017","unstructured":"Sinkou H, Hurevich H, Rusovich V, Zhylevich L, Falzon D, de Colombani P, et al. Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience. Eur Respir J. 2017;49(3):1602049.","journal-title":"Eur Respir J"},{"issue":"11","key":"11151_CR18","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.5588\/ijtld.11.0868","volume":"16","author":"KY Au-Yeung","year":"2012","unstructured":"Au-Yeung KY, DiCarlo L. Cost comparison of wirelessly vs. directly observed therapy for adherence confirmation in anti-tuberculosis treatment. Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis. 2012;16(11):1498\u2013504.","journal-title":"Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis"},{"issue":"3","key":"11151_CR19","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1183\/09031936.00011015","volume":"46","author":"M Mirsaeidi","year":"2015","unstructured":"Mirsaeidi M, Farshidpour M, Banks-Tripp D, Hashmi S, Kujoth C, Schraufnagel D. Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective. Eur Respir J. 2015;46(3):871\u20134.","journal-title":"Eur Respir J"},{"issue":"8","key":"11151_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.5588\/ijtld.21.0170","volume":"25","author":"A Perry","year":"2021","unstructured":"Perry A, Chitnis A, Chin A, Hoffmann C, Chang L, Robinson M, et al. Real-world implementation of video-observed therapy in an urban TB program in the United States. Int J Tuberc Lung Dis. 2021;25(8):655\u201361.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"11151_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.amepre.2010.02.018","volume":"39","author":"JA Hoffman","year":"2010","unstructured":"Hoffman JA, Cunningham JR, Suleh AJ, Sundsmo A, Dekker D, Vago F, et al. Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya. Am J Prev Med. 2010;39(1):78\u201380.","journal-title":"Am J Prev Med"},{"key":"11151_CR22","first-page":"100108","volume":"16","author":"R Lester","year":"2019","unstructured":"Lester R, Park JJ, Bolten LM, Enjetti A, Johnston JC, Schwartzman K, et al. Mobile phone short message service for adherence support and care of patients with tuberculosis infection: evidence and opportunity. J Clin Tuberc Mycobact Dis. 2019;16:100108.","journal-title":"J Clin Tuberc Mycobact Dis"},{"issue":"7","key":"11151_CR23","doi-asserted-by":"publisher","first-page":"e2005","DOI":"10.1093\/cid\/ciaa1198","volume":"73","author":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa","year":"2021","unstructured":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa. Risk factors for Coronavirus Disease 2019 (COVID-19) death in a Population Cohort Study from the Western Cape Province, South Africa. Clin Infect Dis off Publ Infect Dis Soc Am. 2021;73(7):e2005\u201315.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"key":"11151_CR24","volume-title":"Assessment 3 2021 (SHIMS3 2021): final report","author":"Eswatini Population-based HIV Impact","year":"2023","unstructured":"Eswatini Population-based HIV Impact. Assessment 3 2021 (SHIMS3 2021): final report. Mbabane, Eswatini: Ministry of Health of Eswatini; 2023."},{"key":"11151_CR25","unstructured":"The World Bank. The World Bank | World development indicators. Infrastructure. [cited 2022 Nov 13]. https:\/\/databank.worldbank.org\/source\/world-development-indicators"},{"key":"11151_CR26","unstructured":"statistica | Eswatini. price for 1GB mobile data 2022. Statista. [cited 2022 Nov 13]. https:\/\/www.statista.com\/statistics\/1272806\/price-for-mobile-data-in-eswatini\/"},{"issue":"1","key":"11151_CR27","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.4102\/phcfm.v12i1.2257","volume":"12","author":"E Peresu","year":"2020","unstructured":"Peresu E, Heunis CJ, Kigoz GN, De Grave D. Patient satisfaction with directly observed treatment and multidrug-resistant tuberculosis injection administration by lay health workers in rural Eswatini. Afr J Prim Health Care Fam Med. 2020;12(1):2257.","journal-title":"Afr J Prim Health Care Fam Med"},{"key":"11151_CR28","unstructured":"COVID-19 Data Explorer. Our World in Data. [cited 2022 Apr 2]. https:\/\/ourworldindata.org\/coronavirus-data-explorer"},{"key":"11151_CR29","volume-title":"And housing census preliminary results","author":"The 2017 population","year":"2017","unstructured":"The 2017 population. And housing census preliminary results. Mbabane, Eswatini: Central Statistical Office of Eswatini; 2017."},{"key":"11151_CR30","doi-asserted-by":"publisher","unstructured":"Kerschberger B, Telnov A, Yano N, Cox H, Zabsonre I, Kabore SM et al. Successful expansion of community-based drug-resistant TB care in rural Eswatini \u2013 a retrospective cohort study. Trop Med Int Health. 0(0). https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/tmi.13299","DOI":"10.1111\/tmi.13299"},{"key":"11151_CR31","unstructured":"SureAdhere M. Technology, Inc. SureAdhere Mobile Technology, Inc. [cited 2022 Apr 25]. http:\/\/www.sureadhere.com"},{"key":"11151_CR32","unstructured":"World Health Organization. Definitions and reporting framework for tuberculosis \u2013 2013 revision: updated December 2014 and January 2020. D\u00e9finitions et cadre de notification pour la tuberculose \u2013 r\u00e9vision 2013. Geneva: World Health Organization. 2013 [cited 2023 Nov 19]. https:\/\/iris.who.int\/handle\/10665\/79199"},{"key":"11151_CR33","unstructured":"Stata 17, Texas. US: StataCorp LLC; 2021."},{"issue":"1","key":"11151_CR34","doi-asserted-by":"publisher","first-page":"00175","DOI":"10.1183\/23120541.00175-2019","volume":"6","author":"JN Sekandi","year":"2020","unstructured":"Sekandi JN, Buregyeya E, Zalwango S, Dobbin KK, Atuyambe L, Nakkonde D, et al. Video directly observed therapy for supporting and monitoring adherence to tuberculosis treatment in Uganda: a pilot cohort study. ERJ Open Res. 2020;6(1):00175\u20132019.","journal-title":"ERJ Open Res"},{"key":"11151_CR35","unstructured":"Our World in Data. | covid-19-data. GitHub. [cited 2022 Nov 4]. https:\/\/github.com\/owid\/covid-19-data"},{"key":"11151_CR36","unstructured":"Mathieu E, Ritchie H, Rod\u00e9s-Guirao L, Appel C, Giattino C, Hasell J et al. Coronavirus Pandemic (COVID-19) - COVID-19: Stringency Index. Our World in Data. 2020 [cited 2023 May 27]. https:\/\/ourworldindata.org\/covid-stringency-index"},{"issue":"11","key":"11151_CR37","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.3201\/eid2611.203163","volume":"26","author":"GB Migliori","year":"2020","unstructured":"Migliori GB, Thong PM, Akkerman O, Alffenaar JW, \u00c1lvarez-Navascu\u00e9s F, Assao-Neino MM, et al. Worldwide effects of coronavirus disease pandemic on tuberculosis services, January\u2013April 2020. Emerg Infect Dis. 2020;26(11):2709\u201312.","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"11151_CR38","doi-asserted-by":"publisher","first-page":"2001998","DOI":"10.1183\/13993003.01998-2020","volume":"56","author":"D Visca","year":"2020","unstructured":"Visca D, Tiberi S, Pontali E, Spanevello A, Migliori GB. Tuberculosis in the time of COVID-19: quality of life and digital innovation. Eur Respir J. 2020;56(2):2001998.","journal-title":"Eur Respir J"},{"issue":"7","key":"11151_CR39","doi-asserted-by":"publisher","first-page":"e17658","DOI":"10.2196\/17658","volume":"8","author":"X Guo","year":"2020","unstructured":"Guo X, Yang Y, Takiff HE, Zhu M, Ma J, Zhong T, et al. A comprehensive app that improves tuberculosis treatment management through video-observed therapy: Usability Study. JMIR MHealth UHealth. 2020;8(7):e17658.","journal-title":"JMIR MHealth UHealth"},{"key":"11151_CR40","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/S0140-6736(15)00916-2","volume":"386","author":"P Windish","year":"2015","unstructured":"Windish P, Luchenski S, Hall J, Appleby Y, Possas L, Hemming S, et al. Video observed therapy for multidrug-resistant tuberculosis: a qualitative study of patient perspectives. Lancet. 2015;386:S78.","journal-title":"Lancet"},{"issue":"1","key":"11151_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12889-019-7892-9","volume":"20","author":"KK Bommakanti","year":"2020","unstructured":"Bommakanti KK, Smith LL, Liu L, Do D, Cuevas-Mota J, Collins K, et al. Requiring smartphone ownership for mHealth interventions: who could be left out? BMC Public Health. 2020;20(1):81.","journal-title":"BMC Public Health"},{"key":"11151_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ijid.2021.10.029","volume":"113","author":"G Fekadu","year":"2021","unstructured":"Fekadu G, Jiang X, Yao J, You JHS. Cost-effectiveness of video-observed therapy for ambulatory management of active tuberculosis during the COVID-19 pandemic in a high-income country. Int J Infect Dis. 2021;113:271\u20138.","journal-title":"Int J Infect Dis"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11151-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-024-11151-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11151-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T11:02:36Z","timestamp":1717412556000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-024-11151-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["11151"],"URL":"https:\/\/doi.org\/10.1186\/s12913-024-11151-4","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"3 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with the Declaration of Helsinki. The need for informed consent was waived by the ethics committee of the Eswatini Health and Human Research Review Board (EHHRRB) because of the retrospective nature of the study (reference number: EHHRRB088\/2022). This research fulfilled the exemption criteria set by the Institutional M\u00e9decins Sans Fronti\u00e8res Ethics Review Board (ERB) for a posteriori analyses of routinely collected clinical data and thus did not require MSF ERB review. It was conducted with permission from Medical Director, Operational Center Geneva M\u00e9decins Sans Fronti\u00e8res. The form confirming the exemption is attached to the submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"699"}}